Clinical features and prognosis of thymoma with myasthenia gravis: an analysis of 126 patients / 中华放射肿瘤学杂志
Chinese Journal of Radiation Oncology
; (6): 37-41, 2016.
Article
en Zh
| WPRIM
| ID: wpr-490354
Biblioteca responsable:
WPRO
ABSTRACT
Objective To investigate the clinical and pathological features and prognostic factors for thymoma with myasthenia gravis (MG).Methods The clinical and pathological data of 126 patients with thymoma and MG confirmed by postoperative pathological examination from 2008 to 2014 were analyzed retrospectively.The Kaplan-Meier method was used to calculate survival rates;the log-rank test was applied for univariate prognostic analysis;the Cox regression model was applied for multivariate prognostic analysis.Results The numbers of patients who received the follow-up visits at 3 and 5 years were 88 and 45,respectively (the patients who were admitted before the end of October 2011 and the end of October 2009).The 3-and 5-year survival rates were 97.9% and 91.8%,respectively.The 3-and 5-year survival rates for patients with WHO types A+AB+B1 +B2 and B3 were 98.6%/95.2% and 90.6%/92.9%,respectively (P=0.764),and those for patients with Masaoka stages Ⅰ-Ⅱ and Ⅲ-Ⅳ were 98.6%/95.2% and 97.4%/72.7%,respectively (P=0.791).The 3-and 5-year survival rates for patients with complete and partial resection were 97.8%/91.7% and 100.0%/50.0%,respectively (P=0.964),and those for patients with complete resection alone and complete resection+postoperative radiotherapy were 96.8%/93.1% and 100.0%/94.7%,respectively (P=1.000).Conclusions The major treatment modality for thymoma with MG is complete resection followed by radiotherapy according to the specific circumstances after surgery.Complete resection,postoperative radiotherapy,WHO type,and Masaoka stage may be associated with prognosis.
Texto completo:
1
Banco de datos:
WPRIM
Tipo de estudio:
Prognostic_studies
Idioma:
Zh
Año:
2016
Tipo del documento:
Article